

BOLETIM RAMB COVID-19

Número 22
12 de julho de 2020

Can the neutrophil/ lymphocyte ratio (NLR) have a role in the diagnosis of coronavirus 2019 disease (COVID-19)?

*Ahmet Nalbant
Tezcan Kaya
Ceyhun Varim
Selçuk Yaylaci
Ali Tamer
Hakan Cinemre*

Em um momento em que há uma emergência mundial de saúde pública, é fundamental que o conhecimento científico gerado durante a pandemia chegue rapidamente à classe médica classe médica.

Dentro desta dinâmica a Revista da Associação Médica Brasileira (Ramb) está adotando uma série de medidas a fim de acelerar o processo editorial para publicação de artigos sobre a Covid-19. A partir de hoje (14/04/2020), a AMB publicará o Boletim Ramb Covid-19, que antecipará os artigos científicos selecionados pelos editores da Ramb sobre o tema.

“Os artigos foram escritos por especialistas e selecionados dentro dos critérios da Ramb para esclarecer temas fisiopatológicos, assim como oferecer orientações de prevenção e tratamento da doença. Dessa forma, esperamos colaborar com os médicos para o melhor atendimento aos seus pacientes, com a disponibilidade mais ágil desses artigos, antes de sua publicação na Ramb”, comenta Carlos Serrano Jr., editor-chefe da Ramb.

Para o diretor científico da AMB, Antonio Carlos Palandri Chagas, “neste momento ímpar vivido no mundo por conta da pandemia de Covid-19, a AMB cumpre seu papel de estar levando à comunidade científica brasileira os recentes artigos sobre os mecanismos fisiopatológicos e aspectos clínicos relevantes dessa situação que assola a saúde pública”.



Carlos Serrano Jr.



Antonio Carlos Palandri Chagas

EDITORIAL BOARD

EDITORS-IN-CHIEF

Carlos V. Serrano Jr.
José Maria Soares Jr.

CO-EDITOR

Wanderley M. Bernardo

MANAGING EDITOR

César Teixeira

ASSOCIATED EDITORS

Albert Bousso
Sérgio C. Nahas
Auro Del Giglio

SPECIALTY EDITORS

ACUPUNCTURE

Ari Ojeda Ocampo Moré
Pedro Cavalcante
Dirceu de Lavôr Sales
Marcia Lika Yamamura
Hildebrando Sábato
Fernando Claudio Genschow

ALLERGY AND IMMUNOLOGY

Herberto José Chong Neto
Luis Felipe Chiaverini Ensina
Pedro Francisco Giavina-Bianchi Júnior

ANAESTHESIOLOGY

Marcos Antonio Costa de Albuquerque
Maria Angela Tardelli
Maria José Carvalho Carmona
Rogean Rodrigues Nunes

ANGIOLOGY AND VASCULAR SURGERY

Marcelo Fernando Matielo
José Fernando Macedo
José Aderval Aragão
Arno Von Ristow
Daniel Mendes Pinto

CARDIOLOGY

Wolney de Andrade Martins
Olimpio Ribeiro França Neto
Otavio Rizzi Coelho Filho
Pedro Silvio Farsky
Humberto Graner Moreira

CARDIOVASCULAR

Eduardo Augusto Victor Rocha
João Carlos Ferreira Leal
Rui M. S. Almeida

CLINICAL PATHOLOGY / LABORATORY MEDICINE

Álvaro Pulchinelli Júnior
Maria Elizabete Mendes
Marinês Dalla Valle Martino
Silvana Maria Elói Santos

COLOPROCTOLOGY

Fábio G. Campos
Sergio Nahas

DERMATOLOGY

Mauro Yoshiaki Enokihara
Flávia Bittencourt

DIGESTIVE ENDOSCOPY

Adriana Safatle

DIGESTIVE SURGERY

Bruno Zilberstein
Nelson Andreollo
Oswaldo Malafaia
Carlos Eduardo Jacob

EMERGENCY MEDICINE

Hélio Penna Guimarães
Marcus Vinícius de Andrade
Júlio Marchini

ENDOCRINOLOGY AND METABOLISM

Márcio Mancini
Manoel Ricardo Alves Martins

Claudia Leite

Edna Frasson de S. Montero

Eduardo F. Borba

Elias Jirjoss Ilias

Isabela Giuliano

Lucia Pellanda

Paulo Kassab

Werther B. W. de Carvalho

Linamara Batistella

Dimas Ikeoki

Anna Andrei

Maria Laura Costa do Nascimento

Benedito Borges da Silva

FAMILY AND COMMUNITY MEDICINE

Thiago Sarti
Leonardo Fontenelle

GASTROENTEROLOGY

João Galizzi Filho
André Castro Lyra
Raquel Canzi Almada de Souza

GENERAL SURGERY

Luiz Carlos Von Bahten
Pedro Eder Portari Filho
Rodrigo Felipe Ramos

GERIATRICS AND GERONTOLOGY

Vitor Last Pintarelli

GYNAECOLOGY AND OBSTETRICS

César Eduardo Fernandes
Corintio Mariani Neto
Rosiane Mattar
Edmund Chada Baracat

HAND SURGERY

João Baptista Gomes dos Santos
Samuel Ribak
Antonio Carlos da Costa

HEAD AND NECK SURGERY

Antonio Jose Gonçalves
Flávio Carneiro Hojaij
José Guilherme Vartanian
Leandro Luongo Matos

HEMATOLOGY AND HEMOTHERAPY

Fernando Ferreira Costa

HOMEOPATHY

Silvia Irene Waisse Priven

INFECTIOUS DISEASES

Helio Bacha
Alexandre Vargas Schwarzbald

INTENSIVE CARE MEDICINE

Rosane Sonia Goldwasser
Cintia Magalhães Carvalho Grión
Claudio Piras

INTERNAL MEDICINE

Fernando Sabia Tallo
Abrão José Cury Junior

LEGAL MEDICINE AND MEDICAL EXAMINATIONS

Ivan Dieb Miziara
José Jozafra B. Freite

MASTOLOGY

Gil Facina
Rene Aloisio da Costa Vieira
Ruffo de Freitas Junior

MEDICAL GENETICS

Vera Lucia Gil da Silva Lopes

NEUROSURGERY

Luis Alencar B. Borba
Jean Gonçalves de Oliveira
José Carlos Esteves Veiga

José Marcus Rotta

Eberval Gadelha Figueiredo
Benedicto Oscar Colli

NEPHROLOGY

Andrea Pio de Abreu
Vinicius Daher Alvares Delfino
David Jose de Barros Machado

NEUROLOGY

Carlos Roberto de Mello Rieder
Marcondes Cavalcante França Jr.

NUCLEAR MEDICINE

Juliano Julio Cerci
Cristina Sebastião Matushita
George Barberio C. Filho
Rafael Willain Lopes

NUTROLOGY

Elza Daniel de Mello
Juliana Machado
Durval Ribas Filho

OCCUPATIONAL MEDICINE

Francisco Cortes Fernandes
Rosylane Nascimento das Mercês Rocha
Andrea Franco Amoras Magalhães

ONCOLOGY

Daniela Rosa
Markus Gifoni
Romualdo Barroso

OPHTHALMOLOGY

Keila Monteiro de Carvalho
Eduardo Melani Rocha

ORTHOPAEDICS AND TRAUMATOLOGY

Marco Kawamura Demange
Benno Ejnisman
Daniel Soares Baumfeld
Alex Guedes
Robinson Esteves Santos Pires

OTOLARYNGOLOGY

Marcio Nakanishi
Luciano Rodrigues Neves
Vinicius Ribas de Carvalho Duarte
Fonseca
Edson Ibrahim Mitre

PAEDIATRIC

Emanuel Savio Cavalcanti Sarinho
Debora Carla Chong e Silvia
Simone Brasil de Oliveira Iglesias

PAEDIATRIC SURGERY

Maria do Socorro Mendonça de Campos
Lisieux Eyer de Jesus
José Roberto de Souza Baratella

PATHOLOGY

Fernando Augusto Soares
Kátia Ramos Moreira Leite

PHYSICAL MEDICINE AND REHABILITATION

Silvia Verst
Eduardo Rocha
Luciana Dotta

INTERNATIONAL EDITORS

Frida Leonetti
Geltrude Mingrone
Giuseppe Barbaro
Marcelo Marotti
Walter Ageno
Michael Farkouh

JUNIOR EDITORS

Matheus Belloni Torsani
Hélio Amante Miot
Rubens Zeron
Luiz de Menezes Montenegro
Gustavo K. Matsui

Ligia Cattai

Marcus Yu Bin Pai

PLASTIC SURGERY

Ricardo Frota Boggio
Rodrigo Gouvea Rosique
Fabio Kamamoto

PREVENTIVE MEDICINE AND HEALTH ADMINISTRATION

Antonio Eduardo Fernandes D'Aguilar
Milton Massayuki Osaki
Helio Komagata

PSYCHIATRY

Antônio Geraldo da Silva
Itiro Shirakawa
Francisco Baptista Assumpção Junior
Leonardo Rodrigo Baldaçara
Sérgio Tamai

PULMONOLOGY / PHTHISIOLOGY

José Miguel Chatkin
Marcelo Fouad Rabahi
Rodrigo Luis Barbosa Lima
Rosemeri Maurici da Silva

RADIOTHERAPY

Arthur Accioly Rosa
Gustavo Nader Marta
Gustavo Viani Arruda
Mauricio Fraga da Silva

RADIOLOGY

Alair Sarmet
Valdir Muglia
Dante Luiz Escussato
Luciana Costa Silva
Claudia Leite
Manoel Rocha

RHEUMATOLOGY

Eduardo dos Santos Paiva

SPORTS MEDICINE

André Pedrinelli;
Fernando Carmelo Torres
Marcelo Bichels Leitão.

SURGICAL ONCOLOGY

Alexandre Ferreira Oliveira
Reitan Ribeiro
Gustavo Andrezza Laporte

TRAFFIC MEDICINE

José Heverardo da Costa Montal
Arlison de Souza Carvalho Junior
Egas Caparelli Moniz de Aragão Dáquer

THORACIC SURGERY

Darcy Pinto
Carlos Alberto Araujo
Ricardo Terra

UROLOGY

Eduardo Carvalhal
Gilberto Almeida
Stênio Zequi
Lucas Teixeira A. Batista
Francisco Bretas

**ASSOCIAÇÃO MÉDICA BRASILEIRA (BRAZILIAN MEDICAL ASSOCIATION)
MANAGEMENT BOARD 2017-2020**



PRESIDENT

Lincoln Lopes Ferreira (Minas Gerais)

1ST VICE-PRESIDENT

Diogo Leite Sampaio (Mato Grosso)

2ND VICE-PRESIDENT

Robson Freitas de Moura (Bahia)

VICE-PRESIDENTS

José Luiz Dantas Mestrinho – Mid-West (Federal District)

Arno Buertiner Von Ristow – Southeast (Rio de Janeiro)

Eduardo Francisco de Assis Braga – North (Tocantins)

Mauro Cesar Viana de Oliveira – Northeast (Maranhão)

Alfredo Floro Cantalice Neto – South (Rio Grande do Sul)

GENERAL SECRETARY

Antônio Jorge Salomão (São Paulo)

1ST SECRETARY

Carmita Helena Najjar Abdo (São Paulo)

1ST TREASURER

Miguel Roberto Jorge (São Paulo)

2ND TREASURER

José Luiz Bonamigo Filho (São Paulo)

CULTURAL DIRECTOR

Fernando Antonio Gomes de Andrade (Alagoas)

DIRECTOR OF CORPORATE RELATIONS

Carlos Alfredo Lobo Jasmin (Rio de Janeiro)

DIRECTOR OF INTERNATIONAL RELATIONS

Eduardo Nagib Gaudi (Rio de Janeiro)

SCIENTIFIC DIRECTOR

Antonio Carlos Palandri Chagas (São Paulo)

ACADEMIC DIRECTOR

Maria José Martins Maldonado (Mato Grosso do Sul)

DIRECTOR OF MEMBER SUPPORT SERVICES

Marcio Silva Fortini (Minas Gerais)

DIRECTOR OF PARLIAMENTARY AFFAIRS

Débora Eugenia Braga Nóbrega Cavalcanti (Paraíba)

**RAMB - REVISTA DA ASSOCIAÇÃO MÉDICA BRASILEIRA
(JOURNAL OF THE BRAZILIAN MEDICAL ASSOCIATION)**

RAMB

EDITORS-IN-CHIEF: *Carlos V. Serrano Jr. and José Maria Soares Jr.*

CO-EDITOR: *Wanderley M. Bernardo*

MANAGING EDITOR: *César Teixeira*

E-MAIL: *ramb@amb.org.br*

WEBSITE: *www.ramb.org.br*

Address: Rua São Carlos do Pinhal, 324

Bela Vista – São Paulo

Postal Code: 01333-903

Phone no.: (+55 11) 3178-6800 Ext. 177

The RAMB, Journal of The Brazilian Medical Association, is an official publication of the Associação Médica Brasileira (AMB – Brazilian Medical Association), indexed in Medline, Science Citation Index Expanded, Journal Citation Reports, Index Copernicus, Lilacs, and Qualis B2 Capes databases, and licensed by Creative Commons®. Registered in the 1st Office of Registration of Deeds and Documents of São Paulo under n. 1.083, Book B, n. 2.

Publication norms are available on the website www.ramb.org.br

All rights reserved and protected by Law n. 9.610 – 2/19/1998. No part of this publication may be reproduced without prior written authorization of the AMB, whatever the means employed: electronic, mechanical, photocopying, recording or other.

THE RAMB IS INDEXED IN SCIELO - SCIENTIFIC ELECTRONIC LIBRARY ONLINE.



TIMBRO EDITORA

PUBLISHER: *Rodrigo Aguiar*

AUTHORIZING EDITOR: *Luciano Bauer Grohs*

EDITOR: *Celina Maria Morosino Lopes*

PRODUCER: *Maria Fortes*

EDITORIAL PRODUCER: *Helvânia Ferreira*

ENGLISH TRANSLATION OF ARTICLES: *Alpha & Omega*

REFERENCE REVIEWER: *Rosângela Monteiro*

PROOFREADING: *Hebe Ester Lucas e Alpha & Omega*

GRAPHIC DESIGN: *Angela Mendes e Murilo M. Camargo*



The advertisements and opinions published in the Ramb are the sole responsibility of the advertisers and authors. The AMB and Timbro Comunicação are not responsible for its content.

Can the neutrophil/lymphocyte ratio (NLR) have a role in the diagnosis of coronavirus 2019 disease (COVID-19)?

 Ahmet Nalbant¹
 Tezcan Kaya¹
 Ceyhan Varim¹
 Selçuk Yaylacı¹
 Ali Tamer¹
 Hakan Cinemre¹

1. Sakarya University School of Medicine Departments of Internal Medicine.

SUMMARY

OBJECTIVE: The present study aimed to investigate the role of neutrophil/lymphocyte ratio (NLR), an inflammation marker, complete blood count, and biochemical parameters in the diagnosis of COVID-19.

METHODS: A total of 80 patients who had been hospitalized in the internal medicine clinic were enrolled in the study. The cases were allocated into two groups, i.e., COVID (+) and (-), based on real-time reverse transcription-polymerase chain reaction. The demographic, clinical, and laboratory [NLR, platelet/lymphocyte ratio (PLR), complete blood count, biochemistry, and serology] data of the patients were retrospectively obtained from the hospital data management system.

RESULTS: NLR and fever levels were found to be higher in COVID-19 (+) cases ($P=0.021$, $P=0.001$, respectively). There was no difference between males and females with regard to COVID-19 positivity ($P=0.527$). Total bilirubin levels were found to be lower in COVID-19 (+) cases ($P=0.040$). When the ROC analysis was carried out for NLR in COVID-19 (+) cases, the AUC value was found to be 0.660 ($P=0.021$), sensitivity as 69.01%, specificity as 65.40%, LR+: 1.98 and LR-: 0.48, PPV: 80.43, and NPV: 50.00, when the NLR was ≥ 2.4 . The risk of COVID-19 was found to be 20.3-fold greater when NLR was ≥ 2.4 in the logistic regression ($P=0.007$).

CONCLUSION: NLR is an independent predictor for the diagnosis of COVID-19. We also found that fever and total bilirubin measurements could be useful for the diagnosis of COVID-19 in this population.

KEYWORDS: Coronavirus Infections. Coronavirus. Fever. Lymphocytes. Neutrophils.3+q

RESUMO

OBJETIVO: O objetivo do presente estudo foi investigar o papel da razão neutrófilos/linfócitos (RNL), um marcador de inflamação, hemograma completo e parâmetros bioquímicos no diagnóstico de COVID-19.

MÉTODOS: Um total de 80 pacientes internados na clínica médica foram incluídos no estudo. Os casos foram alocados em dois grupos, COVID (+) e (-), de acordo com a reação em cadeia da polimerase com transcrição reversa em tempo real. Os dados demográficos, clínicos e laboratoriais [NLR, relação plaquetas / linfócitos (PLR), hemograma completo, bioquímica e sorologia] dos pacientes foram obtidos retrospectivamente no sistema de gerenciamento de dados hospitalares.

RESULTADOS: Os níveis de NLR e febre foram maiores nos casos de COVID-19 (+) ($P = 0,021$, $P = 0,001$, respectivamente). Não houve diferença entre homens e mulheres em relação à positividade para COVID-19 ($P = 0,527$). Os níveis totais de bilirrubina foram menores nos casos de COVID-19 (+) ($P = 0,040$). Quando a análise ROC foi realizada para NLR nos casos COVID-19 (+), o valor da AUC foi de 0,660 ($P = 0,021$), sensibilidade 69,01%, especificidade 65,40%, LR +: 1,98 e LR-: 0,48, PPV: 80,43 e NPV: 50,00 quando o NLR era $\geq 2,4$. The risk of COVID-19 was found to be 20.3-fold greater when NLR was ≥ 2.4 in the logistic regression ($P=0.007$).

CONCLUSÃO: NLR é um preditor independente para o diagnóstico de COVID-19. Também concluímos que aferições de febre e bilirrubina total podem ser úteis para o diagnóstico de COVID-19 nesta população.

PALAVRAS-CHAVE: Infecções por Coronavirus. Coronavirus. Febre. Linfócitos. Neutrófilos.

INTRODUCTION

Coronaviruses (CoVs) are single-chain, enveloped RNA viruses. They do not contain the RNA polymerase enzyme; however, they encode this enzyme in their genome. They are defined as CoV due to the protrusions on their surface (Latin: corona=crown)¹. Coronaviruses belong to the *Orthocorona-virinae* sub-family and are classified as four types (alpha, beta, gamma, and delta CoVs) and multiple subspecies. Coronavirus 2019 is within the beta-coronavirus 2b strain. The genomes of the *beta-coronaviridae* were shown to be closely related to the bat SARS-like coronavirus². This type of virus may be found in humans, bats, pigs, cats, dogs, remnants, and winged animals³. Coronaviruses are a large virus family that may lead to self-limited, mild, and common infections like the common cold, and also more severe infections like Severe Acute Respiratory Syndrome (SARS)⁴ and Middle East Respiratory Syndrome (MERS)⁵. These viruses may lead to clinical conditions with various degrees of respiratory, enteric, hepatic, nephritic, and neurological involvement.

Pneumonia cases with unknown etiology and of suggested viral origin were reported in Wuhan, Hubei, China on 31 December 2019. The virus was shown in workers of the seafood wholesale market where different animal types are sold. The patients exhibited fever, dyspnea, cough, and, radiologically, bilateral pneumonic infiltrations⁶. Death usually occurred in individuals who were elderly or who had comorbid systemic diseases (hypertension, diabetes mellitus, cardiovascular diseases, cancer, chronic pulmonary diseases, and other immune-suppressive conditions)^{7,8}.

The pathophysiology of the high pathogenicity of this unusual highly contagious SARS-CoV2 could not be

fully understood yet. Inflammation plays an important role in infectious diseases. Accumulating evidence has shown the importance of inflammation in the progression of viral pneumonia, including in coronavirus disease 2019 (COVID-19) cases⁸. Pro-inflammatory cytokines have been shown to increase in sera of patients with pulmonary inflammation⁹. The white blood cell (WBC) count, neutrophil, lymphocyte count, neutrophil/lymphocyte ratio (NLR), and platelet/lymphocyte ratio (PLR) are markers of systemic inflammation^{10,11}. These markers are useful predictors for the prognosis and follow-up of patients with viral pneumonia. NLR is a very useful, rapid, and inexpensive indicator, the significance of which has been shown in bacterial pneumonia¹² and viral infections¹³.

This retrospective, single-center study was conducted to investigate the complete blood count parameters, NLR, PLR, C-reactive protein (CRP), and the other infection bio-markers and biochemical data of a total of 80 COVID-19 positive and negative cases.

METHODS

A total of 80 patients who had been hospitalized at the medical clinic between 01 April 2020 and 25 April 2020 and tested for COVID-19 with real-time reverse transcription-polymerase chain reaction (rRT-PCR) were enrolled in the study. The nasal and pharyngeal swabs of all patients were obtained. Isolated patient samples that were obtained with VNAT viral transport and brought to the molecular virology laboratory were examined using the Biospedy (Bioeksan, Turkey) rRT-PCR kit provided by the Ministry of Health of Turkey. The patients whose rRT-PCR results were positive were regarded as COVID-19 (+), and those whose rRT-PCR results were negative twice with a 48-hour interval were regarded as COVID-19 (-). Hospital records (demographic, clinical, and laboratory data) of the cases above 18 years were analyzed retrospectively. The patients were

divided into two groups, i.e., COVID-19 (+) and COVID-19 (-). Neutrophil, lymphocyte, platelets, MPV, hemoglobin, and CRP values of all patients were recorded, and the NLR and PLR values were calculated. The reports from the thoracic computed tomographies were obtained from the data management system. Serum urea, creatinine, total cholesterol, triglyceride, low-density lipoprotein (LDL)-cholesterol, high-density lipoprotein (HDL)-cholesterol, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and albumin were analyzed using the kinetic alkaline picrate method with the Architect C 16000 (Abbott) device at the biochemistry laboratory of the hospital. The complete blood count parameters were examined with the Celddyn 3700 device. Ethics committee approval was obtained from the Ministry of Health of the Turkish Republic and the Sakarya University Medical School (No: 715224737050.01.04/131; April 04, 2020).

STATISTICAL ANALYSIS

Data analysis was performed by using statistical software (SPSS, version 10.0 [SPSS Inc, Chicago, IL]. Normally distributed data were compared by one-way analysis of variance, and non-normally distributed data were compared via the Mann-Whitney U test. Categorical associations were evaluated by using the χ^2 test and multiple logistic regression. The goodness of fit was determined by using the Nagelkerke R^2 and Hosmer-Lemeshow goodness-of-fit test. The performance of NLR was assessed using receiver operating characteristic (ROC) curve analysis and by calculating the area under the curve (AUC) of the ROC curves. Statistical significance was defined as $P \leq 0.05$.

RESULTS

Of the total 80 patients, 39 (49%) were females and 41 (51%) were males. COVID-19 was determined to be positive in 54 out of the 80 cases (67.5%). The mean age (SD) was 53 (18) years

for COVID-19 (+) patients and 60 (14) for COVID-19 (-) patients, and the difference was not statistically significant ($F=3.029$; $P=0.086$). Similarly, there was no difference between the groups concerning gender ($\chi^2=0.400$ $P=0.527$). Fever was present in 41% of COVID-19 (+) cases. There was a significant difference between the groups concerning HDL-cholesterol values ($F=4.984$; $P=0.031$). The rates of fever, lactate, and ferritin levels were significantly higher in COVID-19 (+) cases compared to COVID-19 (-) cases (Mann-Whitney $U=390.0$, $P<0.001$; 152.0, $P=0.040$; 202.5, $P=0.046$; 396.0, $P=0.008$, respectively). The rates of total bilirubin level were significantly lower in COVID-19 (+) cases (Mann-Whitney $U=152.0$, $P=0.040$). While the NLR, PLR, and CRP values were significantly higher (Mann-Whitney $U=477.5$, $P=0.021$; 508.0, $P=0.046$; 448.5, $P=0.012$, respectively), the lymphocyte count was significantly lower (Mann-Whitney $U=419.0$, $P=0.004$) in COVID-19 (+) cases compared to COVID-19 (-) cases. There was no difference between COVID-19 (+) and (-) cases concerning WBC, neutrophil, platelet count, MPV, and procalcitonin. The demographic and laboratory characteristics of patients infected with and without COVID-19 are shown in Table - I. The mean neutrophil/lymphocyte ratio and fever in COVID-19 (+) and (-) cases are displayed in Figure 1. The effect of NLR on the diagnosis of COVID-19 was analyzed by ROC curve and AUC and was found to be significant (AUC:0.660; $P=0.021$, 95% CI 0.538 to 0.783) (Fig.2). Sensitivity, specificity, positive predictive value, negative NPV, LR+, LR- values, and the disease prevalence for $NLR \geq 2.4$ were 69.01%, 65.40%, 80%, 50%, 1.98, 0.48 and 67.5%, respectively. The effect of fever on the diagnosis of COVID-19 was analyzed by ROC curve and AUC and was found to be significant (AUC:0.722; $P=0.001$, 95% CI 0.606 to 0.838). Sensitivity, specificity, positive predictive value, negative NPV, LR+, LR- values, and the disease prevalence for fever \geq

36.8 were 66.67%, 76.92%, 86%, 43%, 2.98, 0.43 and 67.5%, respectively.

We built a logistic regression model including $NLR \geq 2.4$, temperature ≥ 36.8 , and serum total bilirubin as free predictors of a Covid-19 positive diagnosis. According to our model, the odds ratio for a covid-19-positive result was 20.3 and 10.5 when $NLR > 2.4$ and temperature was > 36.8 ($B=3.011$, Standard Error=1.324, Wald=5.170, Odds ratio=20.3, $P=0.023$ for NLR ; $B=2.356$, Standard Error=1.079, Wald=4.768, Odds ratio=10.5, $P=0.029$ for fever and $B=7.726$, Standard Error=3.141, Wald=6.049, Odds ratio=0.0, $P=0.014$ for serum total bilirubin). The decrease of total serum bilirubin was significant for a covid-19-positive result, but without affecting the odds ratio. Nagelkerke R^2 was 65%.

DISCUSSION

In the present study, we reported the cohort of 54 COVID-19 (+) cases and 26 COVID-19 (-) cases confirmed with laboratory tests. NLR and fever were found to be significantly higher in COVID-19 cases. Total bilirubin levels were found to be lower in COVID-19 cases. There was no difference between COVID-19 (+) and (-) cases concerning age and gender.

Fever is among the most important clinical manifestations of CoV infections. In a study reported in the *Lancet*, fever was detected in 83% of the cases with COVID-19 pneumonia¹⁴; this rate was found to be 43.8% in another study⁷. The rate of fever was found to be 41% in our study. If the definition of case surveillance is mainly focused on the detection of fever, patients may be overlooked in the absence of fever, since fever was not detected in about half of the patients at the beginning. We determined a significant difference between COVID-19 (+) and (-) cases concerning fever. The risk of COVID-19 was found to be 10.5-fold greater when the fever was ≥ 36.8 degrees. Fever and CRP are not only systemic markers of inflammation but also mediators of inflammatory factors¹⁵. CRP was found

TABLE 1. DEMOGRAPHIC AND LABORATORY CHARACTERISTICS OF PATIENTS INFECTED WITH AND WITHOUT COVID-19.

Indicators	COVID-19 (+) n=54	COVID-19 (-) n=26	P-value
Mean age (SD), year	53(18)	60(14)	0.086
Men	29	12	0.635
Women	25	14	0.347
Lymphocyte (IR), K/uL	1.3(0.7)	2.0(1.0)	0.004
NLR median (IR)	4.7(2.8)	2.9(1.7)	0.021
Platelet (IR), K/uL	183(21)	221(43)	0.681
MPV (SD), fl	9(1.3)	9.2(1.1)	0.987
Hemoglobin (SD), gr/dL	12.4(1.7)	11.5(1.8)	0.033
PLR median (IR)	141(22)		0.046
Kreatinin mg/dL	0.8(0.6)	0.6(0.4)	0.703
Total Cholesterol (SD), mg/dL	151(34)	158(49)	0.197
Triglycerides (IR), mg/dL	115(45)	80(23)	0.120
Low-density lipoprotein (SD), mg/dL	95(24)	109(29)	0.099
High-density lipoprotein (SD), mg/dL	30(9)	38(14)	0.031
Alanine aminotransferase (IR), U/L	33(27)	25(22)	0.170
Aspartate (IR), U/L	33(9)	28(8)	0.015
Albumin (SD), mg/dL	3.4(0.5)	3.4(0.6)	0.934
Protrombin zamanı (SD), s	12.7(1.4)	12.3(1.2)	0.304
INR (IR)	1.2(0.3)	1.0(0.2)	0.016
Activated partial thromboplastin time (SD), s	25(2.8)	26(3.4)	0.567
LDH (IR), U/L	322(17)	211(15)	0.016
Creatine kinase (IR), U/L	64(14)	71(18)	0.039
Ferritin (IR) μ g/L	503(131)	108(51)	0.008
Total bilirubin (IR) mg/dL	0.64(0.1)	0.9(0.2)	0.040
d-Dimer (IR), ugFEU/L	633(176)	570(150)	0.934
CRP (IR) mg/L	89(88)	3.1(1.1)	0.012
Procalcitonin (IR)	0.09(0.2)	0.05(0.1)	0.945
Laktat (IR) mmol/L	1.7(1.5)	1.4(1.1)	0.046
Thorax computerize tomography (typical viral pneumonia sign)	10	2	0.204

to be high in COVID-19 patients in a previous study¹⁶. We also found CRP to be significantly high in our study.

The decrease of total serum bilirubin was significant for covid-19-positive results but without affecting the odds ratio. Also, AST levels were significantly higher in COVID-19 cases; however, this increase was not observed for ALT. This was compatible with a study in China^{17,18}. This elevation may be

related to viral load and changes in the liver synthesis capacity. Other causes of changes in liver function include ACE2-mediated direct viral infection of hepatocytes or critically-ill status and immune-mediated injury.

Thrombocytopenia is another pathological finding that could be detected in a complete blood count¹⁹. Thrombocytopenia was detected in our study, consistent with the

FIGURE 1. MEAN NEUTROPHIL TO LYMPHOCYTE RATIO TEMPERATURE IN PATIENTS WITH AND WITHOUT COVID-19.





FIGURE 2. RECEIVER OPERATING CHARACTERISTIC CURVE FOR NEUTROPHIL TO LYMPHOCYTE RATIO IN PATIENTS WITH OR WITHOUT COVID-19.



previous study; furthermore, PLR was significantly high. The platelet count, dynamic changes during treatment, and PLR were a source of concern in severe COVID-19 pneumonia cases. It was interpreted that PLR could serve as a novel indicator of the degree of cytokine storm²⁰.

In a study conducted in China, no difference was found between severe and moderate cases concerning the WBC count in the correlation analysis, and lymphopenia was reported to develop when the WBC count was normal²¹. Consistent with the previous study, we detected lymphopenia when the WBC and the neutrophil count were normal in hospitalized COVID-19 cases.

A decrease was determined in the peripheral blood lymphocyte count of critically ill COVID-19 patients^{9,14,16}. Immune cells infiltrate the lungs and lead to unexplained severe lung infections⁴. In a study, the lymphocyte count was found to be $<1.0 \times 10^9/L$ (9). We found the lymphocyte value as $1.3 \times 10^9/L$, consistent with the previous studies.

The human immune response is created by lymphocytes triggered by viral infections²². Systemic infections

suppress cellular immunity. The novel coronavirus may mainly act on lymphocytes, especially T lymphocytes²³. The total lymphocytes, CD4+ T cells, CD8+ T cells, B cells, and NK cells decreased in COVID-19 patients, and severe cases had lower levels of these cells than mild cases^{22,24}. Therefore, CoV-induced inflammation-related lymphopenia increased NLR. In the only study conducted before ours, the optimal threshold of 3.3 for NLR showed a superior prognostic possibility of clinical symptoms for change from mild to severe⁷. Our study was among the first studies in the literature. We found NLR to be high and the likelihood of COVID-19 was 20-fold greater when NLR was ≥ 2.4 .

The results of rRT-PCR can be obtained in hours; hence the diagnosis and treatment may be delayed. The shortcomings of the PCR method due to false positive/false negative results from insufficient sampling, insufficient laboratory facilities due to the pandemic, samples collected too early or too late, and the binding sites of primer/probe couples used in the rRT-PCR lead to some difficulties in the diagnosis²⁵. However, NLR is

a rapid, inexpensive, and useful indicator that could be estimated via the complete blood count. The clinical use of NLR has been shown in bacterial pneumonia¹² and viral infections¹³. The surveillance of NLR and lymphocyte subsets is helpful in the early screening of critical illness, diagnosis, and treatment of COVID-19¹⁷.

The COVID-19 pandemic may spread rapidly from human-to-human. The clinical characteristics of the disease vary among patients. The severity of the condition may be related to the number of immune cells.

CONCLUSION

In conclusion, we found that NLR was significantly elevated in COVID-19 patients. We also provided a cut-off for this readily available test and showed that patients with NLR ≥ 2.4 were 20.5 times more likely to have COVID-19 compared to patients whose NLR was ≤ 2.4 . Similarly, the likelihood of COVID-19 was 10.5-fold greater when fever was $\geq 36.8^\circ C$. This study indicates that high fever and NLR are independent biomarkers for COVID-19 patients. Our findings may also help in the early diagnosis of COVID-19.

Authors contribution

AN, CV & SY did data collection and manuscript writing; AN, TK & HC conceived, designed, and did the statistical analysis & editing of the manuscript; AT did the review and final approval of the manuscript; AN

takes responsibility and is accountable for all aspects of the work, ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Submitted Date: 21-May-2020

Accepted Date: 23-May-2020

CORRESPONDING AUTHOR:

Ahmet Nalbant

Internal Medicine, Korucuk, Sakarya, Turkey -

54100 Tel:+90 (264) 888-4001 /

Fax: +90 (264) 275-9192

E-mail: drnalbant@hotmail.com

REFERENCES

1. Zhou Y, Yang Y, Huang J, Jiang S, Du L. Advances in MERS-CoV vaccines and therapeutics based on the receptor-binding domain. *Viruses*. 2019;11(1):60.
2. Tan W, Zhao X, Ma X, Wang W, Niu P, Xu W, et al. A novel coronavirus genome identified in a cluster of pneumonia cases — Wuhan, China 2019–2020. *China CDC Weekly*. 2020;2(4):61-2. [cited 2020 May 12]. Available from: <http://weekly.chinacdc.cn/fileCCDCW/journal/article/ccdcw/2020/4/PDF/Wuhan.pdf>
3. Richman DD, Whitley RJ, Hayden FG. *Clinical virology*. 4th ed. Washington: ASM Press; 2017. p.1243-7.
4. Chan JF, Li KS, To KK, Cheng VC, Chen H, Yuen KY. Is the discovery of the novel human betacoronavirus 2c EMC/2012 (HCoV-EMC) the beginning of another SARS-like pandemic? *J Infect*. 2012;65:477-89.
5. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. *N Engl J Med*. 2012;367(19):1814-20.
6. World Health Organization. Novel coronavirus – China. Geneva: World Health Organization; 2020. [cited 2020 May 12]. Available from: <https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/>
7. Yang AP, Liu JP, Tao WQ, Li HM. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. *Int Immunopharmacol*. 2020;84:106504.
8. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al; China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med*. 2020;382(8):727-33.
9. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497-506.
10. Zahorec R. Ratio of neutrophil to lymphocyte counts: rapid and simple parameter of systemic inflammation and stress in critically ill. *Bratisl Lek Listy*. 2001;102(1):5-14.
11. Ying HQ, Deng QW, He BS, Pan YQ, Wang F, Sun HL, et al. The prognostic value of preoperative NLR, d-NLR, PLR and LMR for predicting clinical outcome in surgical colorectal cancer patients. *Med Oncol*. 2014;31(12):305.
12. Yoon NB, Son C, Um SJ. Role of the neutrophil-lymphocyte count ratio in the differential diagnosis between pulmonary tuberculosis and bacterial community-acquired pneumonia. *Ann Lab Med*. 2013;33(2):105-10.
13. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. *Clin Infect Dis*. 2020;ciaa248.
14. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020;395(10223):507-13.
15. Thiele JR, Zeller J, Bannasch H, Stark GB, Peter K, Eisenhardt SU. Targeting C-reactive protein in inflammatory disease by preventing conformational changes. *Mediators Inflamm*. 2015;2015:372432.
16. Kim ES, Chin BS, Kang CK, Kim NJ, Kang YM, Choi JP, et al; Korea National Committee for Clinical Management of COVID-19. Clinical course and outcomes of patients with severe acute respiratory syndrome coronavirus 2 infection: a preliminary report of the first 28 patients from the Korean Cohort Study on COVID-19. *J Korean Med Sci*. 2020;35(13):e142.
17. Feng G, Zheng KI, Yan QQ, Rios RS, Targher G, Byrne CD, et al. COVID-19 and liver dysfunction: current insights and emergent therapeutic strategies. *J Clin Transl Hepatol*. 2020;8(1):18-24.
18. Wong SH, Lui RN, Sung JJ. Covid-19 and the digestive system. *J Gastroenterol Hepatol*. 2020;35(5):744-8.
19. Zhang G, Zhang J, Wang B, Zhu X, Wang Q, Qiu S. Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis. *Respir Res*. 2020;21(1):74.
20. Qu R, Ling Y, Zhang YH, Wei LY, Chen X, Li XM, et al. Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19. *J Med Virol*. 2020;10.1002/jmv.25767.
21. Zhou Y, Zhang Z, Tian J, Xiong S. Risk factors associated with disease progression in a cohort of patients infected with the 2019 novel coronavirus. *Ann Palliat Med*. 2020;9(2):428-36.
22. Rabinowich H, Cohen R, Bruderman I, Steiner Z, Klajman A. Functional analysis of mononuclear cells infiltrating into tumors: lysis of autologous human tumor cells by cultured infiltrating lymphocytes. *Cancer Res*. 1987;47(1):173-7.
23. Menges T, Engel J, Welters I, Wagner RM, Little S, Ruwoldt R, et al. Changes in blood lymphocyte populations after multiple trauma: association with posttraumatic complications. *Crit Care Med*. 1999;27(4):733-40.
24. Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. *J Infect Dis*. 2020;221(11):1762-9.
25. Xiao AT, Tong YX, Gao C, Zhu L, Zhang YJ, Zhang S. dynamic profile of rt-pcr findings from 301 COVID-19 patients in Wuhan, China: a descriptive study. *J Clin Virol*. 2020;127:104346.